Evidence
J Obes Metab Syndr. 2023 Sep 13. doi: 10.7570/jomes23052. Online ahead of print.
ABSTRACT
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the latest term for fatty liver associated with metabolic syndrome. MASLD is as the most common cause of chronic liver disease and is the leading cause of liver-related morbidity and mortality. It is important that all stakeholders be involved in tackling the public health threat of obesity and obesity-related diseases, including MASLD. A simple and clear assessment and referral pathway using non-invasive tests is essential to ensure that patients with severe MASLD are identified and referred to specialist care, while patients with less severe disease remain in primary care, where they are best managed. While lifestyle intervention is the cornerstone of the management of patients with MASLD, cardiovascular disease risk must be properly assessed and managed because cardiovascular disease is the leading cause of mortality. No pharmacological agent has been approved for the treatment of MASLD, but novel anti-hyperglycemic drugs appear to have benefit. Medications used for the treatment of diabetes and other metabolic conditions may need to be adjusted as liver disease progresses to cirrhosis, especially decompensated cirrhosis. Based on non-invasive tests, the concepts of compensated advanced chronic liver disease and clinically significant portal hypertension provide a practical approach to risk stratifying patients according to liver-related complications and can help manage such patients. Finally, prevention and management of sarcopenia should be considered in the management of patients with MASLD.
PMID:37700494 | DOI:10.7570/jomes23052
Estimated reading time: 5 minute(s)
Latest: Psychiatryai.com #RAISR4D
Cool Evidence: Engaging Young People and Students in Real-World Evidence
Real-Time Evidence Search [Psychiatry]
AI Research
Metabolic Dysfunction-Associated Steatotic Liver Disease: A State-of-the-Art Review
🌐 90 Days
VR Related Evidence Matrix
- Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics
- Epidemiology, screening, and Co-management of type 2 diabetes mellitus and Metabolic-dysfunction associated steatotic liver disease
- Incretin-based investigational therapies for the treatment of MASLD/MASH
- Associations of dietary sugars with liver stiffness in Latino adolescents with obesity differ on PNPLA3 and liver disease severity
- The double roles of T cell-mediated immune response in the progression of MASLD
- Spatial genomics: mapping human steatotic liver disease
- Prognostic value of metabolic dysfunction-associated steatotic liver disease over coronary computed tomography angiography findings: comparison with no-alcoholic fatty liver disease
- Anxiety and depression in metabolic-associated steatotic liver disease: relation with socio-demographic features and liver disease severity
- Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD)
- Coronary artery disease as a risk factor for metabolic dysfunction-associated steatotic liver disease and liver fibrosis
- Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: A systematic review
- Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: A systematic review
- Prevalence of at-risk MASH, MetALD and alcohol-associated steatotic liver disease in the general population
- Hepatic extracellular ATP/adenosine dynamics in zebrafish models of alcoholic and metabolic steatotic liver disease
- Metabolic-dysfunction associated steatotic liver disease-related diseases, cognition and dementia: A two-sample mendelian randomization study
- COVID-19 in Individuals with Chronic Liver Diseases
- THE GLOBAL EPIDEMIOLOGY OF NON-ALCOHOLIC FATTY LIVER DISEASE AND NON-ALCOHOLIC STEATOHEPATITIS AMONG PATIENTS WITH TYPE 2 DIABETES
- Analysis of non-alcoholic fatty liver disease differences from metabolic dysfunction-associated fatty liver disease based on clinical features
- Factors associated with high costs of patients with metabolic dysfunction-associated steatotic liver disease: an observational study using the French CONSTANCES cohort
- Electrocardiographic Abnormalities in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis
- Clinical status and challenges of new drugs for metabolic dysfunction-associated fatty liver disease
- Evaluation of the Diagnostic Utility of Selected Serum Adipokines and Cytokines in Subjects with MASLD-A Pilot Study
- The fatty acid omega hydroxylase genes (CYP4 family) in the progression of metabolic dysfunction-associated steatotic liver disease (MASLD): An RNA sequence database analysis and review
- Update in lean metabolic dysfunction-associated steatotic liver disease
- Update in lean metabolic dysfunction-associated steatotic liver disease
- Metabolic-Associated Steatotic Liver Disease (MASLD): A New Term for a More Appropriate Therapy in Pediatrics?
- Impact of pemafibrate in patients with metabolic dysfunction-associated steatotic liver disease complicated by dyslipidemia: A single-arm prospective study
- COMPARISON OF GUT MICROBIOTA IN ALCOHOLIC AND METABOLIC-DYSFUNCION ASSOCIATED STEATOTIC LIVER DISEASE IN ANIMAL MODELS
- Lipid-based insulin-resistance markers predict cardiovascular events in metabolic dysfunction associated steatotic liver disease
- Relationship between Helicobacter pylori infection and risk of metabolic dysfunction-associated steatotic liver disease: An updated meta-analysis
- Association between the skeletal muscle mass to visceral fat area ratio and metabolic dysfunction-associated fatty liver disease: A cross-sectional study of NHANES 2017-2018
- Cognitive dysfunction in early experimental metabolic dysfunction-associated steatotic liver disease is associated with systemic inflammation and neuroinflammation
- Long-term effects of ipragliflozin and pioglitazone on metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes: 5 year observational follow-up of a randomized, 24 week, active-controlled trial: Effect of…
- Changes in the etiology of liver cirrhosis and the corresponding management strategies
- Imbalance of mitochondrial fusion in peripheral blood mononuclear cells is associated with liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis
- Effects of silymarin use on liver enzymes and metabolic factors in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis
- Associations between serum ferritin baselines and trajectories and the incidence of metabolic dysfunction-associated steatotic liver disease: a prospective cohort study
- Adding a Leafy Vegetable Fraction to Diets Decreases the Risk of Red Meat Mortality in MASLD Subjects: Results from the MICOL Cohort
- Association between metabolic dysfunction-associated steatotic liver disease and risk of incident pancreatic cancer: a systematic review and meta-analysis of cohort studies
- Accuracy of prognostic serological biomarkers in predicting liver fibrosis severity in people with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of over 40,000 participants
- Fish oil supplementation during pregnancy decreases liver endocannabinoid system and lipogenic markers in newborn rats exposed to maternal high-fat diet
- The Effects of Synbiotics on the Liver Steatosis, Inflammation, and Gut Microbiome of Metabolic Dysfunction-associated Liver Disease Patients-Randomized trial
- Galectin-3 and Severity of Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease
- Independent and joint association of physical activity and adequate weekday sleep duration with metabolic dysfunction-associated steatotic liver disease
- Digital pathology and spatial omics in steatohepatitis: Clinical applications and discovery potentials
- Inflammatory liver diseases and susceptibility to sepsis
- Interplay between metabolic dysfunction-associated fatty liver disease and renal function: An intriguing pediatric perspective
- Screening for social determinants of health among populations at risk for MASLD: a scoping review
- Circulating total and H-specific GDF15 levels are elevated in subjects with MASLD but not in hyperlipidemic but otherwise metabolically healthy subjects with obesity
- MAFLD as part of systemic metabolic dysregulation
- MAFLD as part of systemic metabolic dysregulation
- Exploring the mechanism of dendrobine in treating metabolic associated fatty liver disease based on network pharmacology and experimental validation
- Impact of the diagnosis of metabolic dysfunction-associated fatty liver disease and non-alcoholic fatty liver disease in patients undergoing liver transplantation for hepatocellular carcinoma
- Intestinal Barrier Dysfunction and Gut Microbiota in Non-Alcoholic Fatty Liver Disease: Assessment, Mechanisms, and Therapeutic Considerations
- Ticagrelor, but Not Clopidogrel, Attenuates Hepatic Steatosis in a Model of Metabolic Dysfunction-Associated Steatotic Liver Disease
- Alcohol Drinking Impacts on Adiposity and Steatotic Liver Disease: Concurrent Effects on Metabolic Pathways and Cardiovascular Risks
- From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences
- Disparate outcomes in Hispanic patients with metabolic dysfunction-associated steatotic liver disease/steatohepatitis and type 2 diabetes: Large cohort study
- Three-Dimensional Structure of Novel Liver Cancer Biomarker Liver Cancer-Specific Serine Protease Inhibitor Kazal (LC-SPIK) and Its Performance in Clinical Diagnosis of Hepatocellular Carcinoma (HCC)
- Liver-specific mitochondrial amidoxime-reducing component 1 (Mtarc1) knockdown protects the liver from diet-induced MASH in multiple mouse models
- Spleen volume is independently associated with non-alcoholic fatty liver disease, liver volume and liver fibrosis
- Research progress in the regulation of pathogenesis and the transformation of chronic liver disease by short-chain fatty acids
- Muscle Quality as a Potential Diagnostic Marker of Advanced Liver Fibrosis in Patients with Non-alcoholic Fatty Liver Disease
- Non-invasive tools for liver steatosis and steatohepatitis predict incidence of diabetes, cardiovascular disease and mortality 20 years later: The ATTICA cohort study (2002-2022)
Evidence Blueprint
Metabolic Dysfunction-Associated Steatotic Liver Disease: A State-of-the-Art Review
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Metabolic Dysfunction-Associated Steatotic Liver Disease: A State-of-the-Art Review
🌐 365 Days
VR Related Evidence Matrix
- Mitochondrial Quality Control: Its Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
- Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics
- Frontiers of Collaboration between Primary Care and Specialists in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review
- Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease
- Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease
- Metabolism-related signalling pathways involved in the pathogenesis and development of metabolic dysfunction-associated steatotic liver disease
- Epidemiology, screening, and Co-management of type 2 diabetes mellitus and Metabolic-dysfunction associated steatotic liver disease
- Effect of the nomenclature of non-alcoholic fatty liver disease on diagnosis and treatment of fatty liver disease concomitant with other liver diseases
- Association of metabolic-dysfunction associated steatotic liver disease with polycystic ovary syndrome
- MASLD: a systemic metabolic disorder with cardiovascular and malignant complications
- Metabolic disease and the liver: A review
- Screening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice
- From metabolic dysfunction-associated fatty liver disease to metabolic dysfunction-associated steatotic liver disease: Controversy and consensus
- Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease
- MELD-Na score may underestimate disease severity and risk of death in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)
- Incretin-based investigational therapies for the treatment of MASLD/MASH
- Associations of dietary sugars with liver stiffness in Latino adolescents with obesity differ on PNPLA3 and liver disease severity
- The double roles of T cell-mediated immune response in the progression of MASLD
- Spatial genomics: mapping human steatotic liver disease
- Therapeutic management of metabolic dysfunction associated steatotic liver disease
- Potential Mechanisms Involving in the Pathogenesis of MASLD and Targets for Pharmacotherapy. Advancements in Metabolic Associated Steatotic Liver Disease (MASLD) Research: Diagnostics, Small Molecule Developments and Future Directions
- Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity
- From Liver to Brain: How MAFLD/MASLD Impacts Cognitive Function
- Dietary and pharmacological treatment in patients with metabolic-dysfunction associated steatotic liver disease
- Fatty liver disease's renaming impacts on drug clinical trials
- The pathophysiology of MASLD: an immunometabolic perspective
- Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease
- Prognostic value of metabolic dysfunction-associated steatotic liver disease over coronary computed tomography angiography findings: comparison with no-alcoholic fatty liver disease
- Anxiety and depression in metabolic-associated steatotic liver disease: relation with socio-demographic features and liver disease severity
- Prevalence, distribution and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings
- Comparison of NAFLD, MAFLD and MASLD characteristics and mortality outcomes in United States adults
- Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD)
- Coronary artery disease as a risk factor for metabolic dysfunction-associated steatotic liver disease and liver fibrosis
- Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study
- Steatotic liver disease is the most important somatic determinant of quality of life in patients with obesity: A cross-sectional study
- Brazilian evidence-based guideline for screening, diagnosis, treatment, and follow-up of metabolic dysfunction-associated steatotic liver disease (MASLD) in adult individuals with overweight or obesity: A joint position statement from the…
- Breaking new ground: MASLD vs. MAFLD-which holds the key for risk stratification?
- Liver and atherosclerotic risks of patients with cryptogenic steatotic liver disease
- Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: A systematic review
- Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: A systematic review
- Gut commensal Kineothrix alysoides mitigates liver dysfunction by restoring lipid metabolism and gut microbial balance
- A narrative review about cognitive impairment in Metabolic Dysfunction-Associated Liver Disease (MASLD): Another matter to face through a holistic approach
- A narrative review about cognitive impairment in Metabolic Dysfunction-Associated Liver Disease (MASLD): Another matter to face through a holistic approach
- BDE-47 induces metabolic dysfunction-associated steatotic liver disease (MASLD) through CD36-mediated increased fatty acid uptake and PPARα-induced abnormal fatty acid oxidation in BALB/c mice
- Effect of Concurrent Metabolic Dysfunction-Associated Steatotic Liver Disease on Serial Non-invasive Fibrosis Markers in Chronic Hepatitis B
- Hepatic Fibrosis and Cancer: The Silent Threats of Metabolic Syndrome
- Prevalence of at-risk MASH, MetALD and alcohol-associated steatotic liver disease in the general population
- Adipose-derived extracellular vesicles - a novel cross-talk mechanism in insulin resistance, non-alcoholic fatty liver disease, and polycystic ovary syndrome
- Unmasking the enigma of lipid metabolism in metabolic dysfunction-associated steatotic liver disease: from mechanism to the clinic
- Hepatic extracellular ATP/adenosine dynamics in zebrafish models of alcoholic and metabolic steatotic liver disease
- The Global Epidemic of Metabolic Fatty Liver Disease
- Apelin and the gut microbiome: Potential interaction in human MASLD
- Interactions between the metabolic syndrome and alcohol consumption increases the risk of liver disease
- Metabolic-dysfunction associated steatotic liver disease-related diseases, cognition and dementia: A two-sample mendelian randomization study
- Metabolic dysfunction-associated steatotic liver disease facilitates hepatitis B surface antigen seroclearance and seroconversion
- COVID-19 in Individuals with Chronic Liver Diseases
- THE GLOBAL EPIDEMIOLOGY OF NON-ALCOHOLIC FATTY LIVER DISEASE AND NON-ALCOHOLIC STEATOHEPATITIS AMONG PATIENTS WITH TYPE 2 DIABETES
- Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver disease
- Metabolic Muddle. MASLD and MASH on the Horizon
- Analysis of non-alcoholic fatty liver disease differences from metabolic dysfunction-associated fatty liver disease based on clinical features
- Factors associated with high costs of patients with metabolic dysfunction-associated steatotic liver disease: an observational study using the French CONSTANCES cohort
- Electrocardiographic Abnormalities in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis
- Metabolic dysfunction-associated steatotic liver disease (MASLD) definition is better than MAFLD criteria for lean patients with non-alcoholic fatty liver disease (NAFLD)
- Clinical status and challenges of new drugs for metabolic dysfunction-associated fatty liver disease